Corvus Pharmaceuticals (CRVS) Retained Earnings (2015 - 2026)

Corvus Pharmaceuticals' Retained Earnings history runs 12 years deep, the most recent figure standing at -$426.0 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 33870.1% year-over-year to -$426.0 million in Q1 2026; TTM through Mar 2026 was -$426.0 million, a 33870.1% decrease from a year earlier, with the FY2025 full-year figure at -$412.3 million, down 195.69% from the prior year.
• Retained Earnings slipped to -$426.0 million in Q1 2026 per CRVS's latest filing, from -$412.3 million in the prior quarter.
• Across five years, Retained Earnings topped out at $430.9 million in Q4 2024 and bottomed at -$426.0 million in Q1 2026.
• The 5-year median for Retained Earnings is -$1.3 million (2024), against an average of -$138.4 million.
• Across the five-year window, Retained Earnings plunged 331063.86% in 2022 and jumped 44656.26% in 2024, its largest moves.
• Year by year, Retained Earnings stood at -$563000.0 in 2022, then sank by 71.76% to -$967000.0 in 2023, then soared by 44656.26% to $430.9 million in 2024, then plunged by 195.69% to -$412.3 million in 2025, then slipped by 3.32% to -$426.0 million in 2026.
• Per Business Quant, the three latest CRVS Retained Earnings figures stand at -$426.0 million (Q1 2026), -$412.3 million (Q4 2025), and -$1.1 million (Q3 2025).